To evaluate treatment efficacy after switching medication in reflux esophagitis patients who have parsistent gastro- esophageal reflux symptoms despite standard PPI therapy - To evaluate treatment efficacy after switching medication in PPI refractory GERD patients

The Jikei University School of Medicine0 个研究点目标入组 15 人开始时间: 2012年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)The patient has warning signs such as vomiting and gastrointestinal hemorrhage. (2)The patient needs to continue any drug that might interact with esomeprazole. (3)The patient previously had or currently has any of the following diseases. Zollinger-Ellison syndrome Esophageal stenosis Esophageal achalasia Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction (4)The patient has any serious hepatic, renal, or cardiac disease that makes participation in the study difficult in the opinion of the investigator. (5)The patient has a confirmed or suspected malignant lesion. (6)The patient is a pregnant, nursing, or possibly pregnant woman. (7)The patient is otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion.

发起方